A citation-based method for searching scientific literature

Caryn Lerman, Robert A Schnoll, Larry W Hawk, Paul Cinciripini, Tony P George, E Paul Wileyto, Gary E Swan, Neal L Benowitz, Daniel F Heitjan, Rachel F Tyndale. Lancet Respir Med 2015
Times Cited: 180







List of co-cited articles
865 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Delia Dempsey, Piotr Tutka, Peyton Jacob, Faith Allen, Kerri Schoedel, Rachel F Tyndale, Neal L Benowitz. Clin Pharmacol Ther 2004
313
37

Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.
Robert A Schnoll, Freda Patterson, E Paul Wileyto, Rachel F Tyndale, Neal Benowitz, Caryn Lerman. Pharmacol Biochem Behav 2009
156
32

Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.
Caryn Lerman, Rachel Tyndale, Freda Patterson, E Paul Wileyto, Peter G Shields, Angela Pinto, Neal Benowitz. Clin Pharmacol Ther 2006
202
32

Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.
F Patterson, R A Schnoll, E P Wileyto, A Pinto, L H Epstein, P G Shields, L W Hawk, R F Tyndale, N Benowitz, C Lerman. Clin Pharmacol Ther 2008
131
24

Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers.
Meghan J Chenoweth, Maria Novalen, Larry W Hawk, Robert A Schnoll, Tony P George, Paul M Cinciripini, Caryn Lerman, Rachel F Tyndale. Cancer Epidemiol Biomarkers Prev 2014
74
29

Reproducibility of the nicotine metabolite ratio in cigarette smokers.
Gideon St Helen, Maria Novalen, Daniel F Heitjan, Delia Dempsey, Peyton Jacob, Adel Aziziyeh, Victoria C Wing, Tony P George, Rachel F Tyndale, Neal L Benowitz. Cancer Epidemiol Biomarkers Prev 2012
80
27

Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.
M K Ho, J C Mwenifumbo, N Al Koudsi, K S Okuyemi, J S Ahluwalia, N L Benowitz, R F Tyndale. Clin Pharmacol Ther 2009
121
21

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
Robert M Anthenelli, Neal L Benowitz, Robert West, Lisa St Aubin, Thomas McRae, David Lawrence, John Ascher, Cristina Russ, Alok Krishen, A Eden Evins. Lancet 2016
464
21

A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism.
Anu Loukola, Jadwiga Buchwald, Richa Gupta, Teemu Palviainen, Jenni Hällfors, Emmi Tikkanen, Tellervo Korhonen, Miina Ollikainen, Antti-Pekka Sarin, Samuli Ripatti,[...]. PLoS Genet 2015
74
25

Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.
Cheyenne E Allenby, Kelly A Boylan, Caryn Lerman, Mary Falcone. J Neuroimmune Pharmacol 2016
35
51

Nicotine chemistry, metabolism, kinetics and biomarkers.
Neal L Benowitz, Janne Hukkanen, Peyton Jacob. Handb Exp Pharmacol 2009
738
18

Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation.
Julie-Anne Tanner, Maria Novalen, Peter Jatlow, Marilyn A Huestis, Sharon E Murphy, Jaakko Kaprio, Aino Kankaanpää, Laurence Galanti, Cristiana Stefan, Tony P George,[...]. Cancer Epidemiol Biomarkers Prev 2015
54
33

Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.
Meghan J Chenoweth, Jennifer J Ware, Andy Z X Zhu, Christopher B Cole, Lisa Sanderson Cox, Nikki Nollen, Jasjit S Ahluwalia, Neal L Benowitz, Robert A Schnoll, Larry W Hawk,[...]. Addiction 2018
26
69

The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.
T F Heatherton, L T Kozlowski, R C Frecker, K O Fagerström. Br J Addict 1991
17

Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine.
Mehmet Sofuoglu, Aryeh I Herman, Haleh Nadim, Peter Jatlow. Neuropsychopharmacology 2012
83
19

Role of human cytochrome P4502A6 in C-oxidation of nicotine.
M Nakajima, T Yamamoto, K Nunoya, T Yokoi, K Nagashima, K Inoue, Y Funae, N Shimada, T Kamataki, Y Kuroiwa. Drug Metab Dispos 1996
341
15

Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine.
Gary E Swan, Christina N Lessov-Schlaggar, Andrew W Bergen, Yungang He, Rachel F Tyndale, Neal L Benowitz. Pharmacogenet Genomics 2009
65
23

Nicotine addiction.
Neal L Benowitz. N Engl J Med 2010
786
14

Metabolism and disposition kinetics of nicotine.
Janne Hukkanen, Peyton Jacob, Neal L Benowitz. Pharmacol Rev 2005
14

Female sex and oral contraceptive use accelerate nicotine metabolism.
Neal L Benowitz, Christina N Lessov-Schlaggar, Gary E Swan, Peyton Jacob. Clin Pharmacol Ther 2006
320
14


Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level.
Andrew A Strasser, Neal L Benowitz, Angela G Pinto, Kathy Z Tang, Stephen S Hecht, Steve G Carmella, Rachel F Tyndale, Caryn E Lerman. Cancer Epidemiol Biomarkers Prev 2011
90
14

Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI.
Deborah W Tang, Brian Hello, Margaret Mroziewicz, Lesley K Fellows, Rachel F Tyndale, Alain Dagher. Neuroimage 2012
41
31

Variation in CYP2A6 Activity and Personalized Medicine.
Julie-Anne Tanner, Rachel F Tyndale. J Pers Med 2017
62
20

Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers.
Amanda Kaufmann, Brian Hitsman, Patricia M Goelz, Anna Veluz-Wilkins, Sonja Blazekovic, Lindsay Powers, Frank T Leone, Peter Gariti, Rachel F Tyndale, Robert A Schnoll. Addict Behav 2015
29
41

Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.
M Nakajima, T Yamamoto, K Nunoya, T Yokoi, K Nagashima, K Inoue, Y Funae, N Shimada, T Kamataki, Y Kuroiwa. J Pharmacol Exp Ther 1996
231
12

Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.
Lisa Sanderson Cox, Nicole L Nollen, Matthew S Mayo, Won S Choi, Babalola Faseru, Neal L Benowitz, Rachel F Tyndale, Kolawole S Okuyemi, Jasjit S Ahluwalia. J Natl Cancer Inst 2012
59
20

Stability of the nicotine metabolite ratio in ad libitum and reducing smokers.
Marc E Mooney, Zhong-Ze Li, Sharon E Murphy, Paul R Pentel, Chap Le, Dorothy K Hatsukami. Cancer Epidemiol Biomarkers Prev 2008
40
30

Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
Kate Cahill, Sarah Stevens, Rafael Perera, Tim Lancaster. Cochrane Database Syst Rev 2013
695
12

Long-term nicotine replacement therapy: a randomized clinical trial.
Robert A Schnoll, Patricia M Goelz, Anna Veluz-Wilkins, Sonja Blazekovic, Lindsay Powers, Frank T Leone, Peter Gariti, E Paul Wileyto, Brian Hitsman. JAMA Intern Med 2015
72
16

Nicotine metabolite ratio as a predictor of cigarette consumption.
Neal L Benowitz, Ovide F Pomerleau, Cynthia S Pomerleau, Peyton Jacob. Nicotine Tob Res 2003
136
11

Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy.
C Lerman, C Jepson, E P Wileyto, F Patterson, R Schnoll, M Mroziewicz, N Benowitz, R F Tyndale. Clin Pharmacol Ther 2010
79
13

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
David Gonzales, Stephen I Rennard, Mitchell Nides, Cheryl Oncken, Salomon Azoulay, Clare B Billing, Eric J Watsky, Jason Gong, Kathryn E Williams, Karen R Reeves. JAMA 2006
992
11

Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.
Catherine A Wassenaar, Qiong Dong, Qingyi Wei, Christopher I Amos, Margaret R Spitz, Rachel F Tyndale. J Natl Cancer Inst 2011
134
11


Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk.
Yesha M Patel, Sunghim L Park, Younghun Han, Lynne R Wilkens, Heike Bickeböller, Albert Rosenberger, Neil Caporaso, Maria Teresa Landi, Irene Brüske, Angela Risch,[...]. Cancer Res 2016
39
25


Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence.
Oliver West, Peter Hajek, Hayden McRobbie. Psychopharmacology (Berl) 2011
35
28

Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.
Timothy B Baker, Megan E Piper, James H Stein, Stevens S Smith, Daniel M Bolt, David L Fraser, Michael C Fiore. JAMA 2016
109
10

Signs and symptoms of tobacco withdrawal.
J R Hughes, D Hatsukami. Arch Gen Psychiatry 1986
10


Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial.
Robert A Schnoll, Freda Patterson, E Paul Wileyto, Daniel F Heitjan, Alexandra E Shields, David A Asch, Caryn Lerman. Ann Intern Med 2010
90
11

Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent.
Jadwiga Buchwald, Meghan J Chenoweth, Teemu Palviainen, Gu Zhu, Christian Benner, Scott Gordon, Tellervo Korhonen, Samuli Ripatti, Pamela A F Madden, Terho Lehtimäki,[...]. Mol Psychiatry 2021
22
45

The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.
Joseph Bloom, Anthony L Hinrichs, Jen C Wang, Linda B von Weymarn, Evan D Kharasch, Laura J Bierut, Alison Goate, Sharon E Murphy. Pharmacogenet Genomics 2011
63
14

Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.
David P King, Sara Paciga, Eve Pickering, Neal L Benowitz, Laura J Bierut, David V Conti, Jaakko Kaprio, Caryn Lerman, Peter W Park. Neuropsychopharmacology 2012
70
12

Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.
Li-Shiun Chen, Timothy B Baker, Megan E Piper, Naomi Breslau, Dale S Cannon, Kimberly F Doheny, Stephanie M Gogarten, Eric O Johnson, Nancy L Saccone, Jen C Wang,[...]. Am J Psychiatry 2012
97
9

Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries.
James W Baurley, Christopher K Edlund, Carissa I Pardamean, David V Conti, Ruth Krasnow, Harold S Javitz, Hyman Hops, Gary E Swan, Neal L Benowitz, Andrew W Bergen. Nicotine Tob Res 2016
24
37


Measures of abstinence in clinical trials: issues and recommendations.
John R Hughes, Josue P Keely, Ray S Niaura, Deborah J Ossip-Klein, Robyn L Richmond, Gary E Swan. Nicotine Tob Res 2003
904
9

The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race.
Robert A Schnoll, Tony P George, Larry Hawk, Paul Cinciripini, Paul Wileyto, Rachel F Tyndale. Psychopharmacology (Berl) 2014
43
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.